Boston Scientific: SIRT: The versatility of current HCC treatment & the opportunities for the future - Digital Liver Cancer Summit 2021
View
Liver Tumours
6
Boston Scientific: SIRT: The versatility of current HCC treatment & the opportunities for the future - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020
View
Liver Tumours
5
Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020
View
Liver Tumours
5
Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020
View
Liver Tumours
5
Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020
View
Liver Tumours
5
Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
